Polypid Ltd (PYPD)

$4.02 +0.12 (3.08%)
Market Cap 63.91M
Revenue (ttm) 0.00
Net Income (ttm) -29.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 22,600
Avg Vol 81,234
Day's Range N/A - N/A
Shares Out 15.90M
Stochastic %K 62%
Beta 1.49
Analysts Strong Sell
Price Target $12.25

Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 4719 5700
Address:
18 Hasivim Street, Petah Tikva, Israel
Finnish_boy
Finnish_boy Dec. 26 at 2:54 PM
$PYPD
0 · Reply
ThermalTideT
ThermalTideT Dec. 26 at 2:44 PM
$PYPD Market structure is quietly punishing unfocused strategies. Operating rhythm should stabilize as learning cycles compress. Overextension would degrade optionality during downturns. Stronger outcomes appear only when priorities stay focused.
0 · Reply
tkcomputer
tkcomputer Dec. 23 at 5:57 PM
$PYPD Can't believe this was over a $200 stock a few years back! Understand there are probably stock splits in there somewhere but alot of people must have bought into their technology at some point!
2 · Reply
Finnish_boy
Finnish_boy Dec. 23 at 3:22 PM
$PYPD
0 · Reply
PaulWalter
PaulWalter Dec. 23 at 12:56 PM
$PYPD weird how mr market doesn’t recognise this. At all. .
2 · Reply
Finnish_boy
Finnish_boy Dec. 23 at 8:13 AM
$PYPD In a month US partnership deal, waiting is coming to end.. they are hiring loads of people on LinkedIn
0 · Reply
Finnish_boy
Finnish_boy Dec. 18 at 9:37 PM
$PYPD
0 · Reply
Finnish_boy
Finnish_boy Dec. 18 at 1:04 AM
$PYPD Tick tock, US partnership deal within a month! https://www.pharmanow.live/latest-news/polypid-brooke-story-chair
0 · Reply
Finnish_boy
Finnish_boy Dec. 16 at 7:30 PM
$PYPD $10 stock in 3 months !!
0 · Reply
PaulWalter
PaulWalter Dec. 16 at 4:41 PM
$PYPD So they’re just hiring someone to negotiate NOW????
2 · Reply
Latest News on PYPD
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dec 16, 2025, 8:30 AM EST - 10 days ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript

Dec 10, 2025, 4:42 PM EST - 15 days ago

PolyPid Ltd. (PYPD) Discusses the Science and Business Case for D-PLEX100 in Tackling Surgical Site Infections Transcript

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

Dec 3, 2025, 8:30 AM EST - 23 days ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Nov 25, 2025, 8:30 AM EST - 4 weeks ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 12:51 PM EST - 6 weeks ago

PolyPid Ltd. (PYPD) Q3 2025 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 7:30 AM EST - 6 weeks ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Nov 6, 2025, 8:30 AM EST - 7 weeks ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Oct 29, 2025, 8:30 AM EDT - 2 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 30, 2025, 8:45 AM EDT - 3 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 8:44 AM EDT - 3 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 16, 2025, 8:30 AM EDT - 3 months ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 4 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Sep 2, 2025, 8:30 AM EDT - 4 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:52 PM EDT - 4 months ago

PolyPid Ltd. (PYPD) Q2 2025 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 7:30 AM EDT - 4 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Aug 12, 2025, 8:00 AM EDT - 4 months ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 30, 2025, 8:00 AM EDT - 5 months ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jul 15, 2025, 8:00 AM EDT - 5 months ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 16, 2025, 7:20 PM EDT - 6 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:42 AM EDT - 7 months ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 7 months ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 8:54 AM EDT - 7 months ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 9, 2025, 7:30 AM EDT - 7 months ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

Jun 6, 2025, 4:05 PM EDT - 7 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 30, 2025, 10:12 AM EDT - 7 months ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 20, 2025, 7:00 AM EDT - 7 months ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

May 14, 2025, 1:24 PM EDT - 8 months ago

PolyPid Ltd. (PYPD) Q1 2025 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 14, 2025, 7:00 AM EDT - 8 months ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 29, 2025, 7:00 AM EDT - 8 months ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

PolyPid to Participate in The Citizens Life Sciences Conference

Apr 22, 2025, 7:00 AM EDT - 8 months ago

PolyPid to Participate in The Citizens Life Sciences Conference

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 11, 2025, 7:00 AM EDT - 10 months ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 7:00 AM EST - 10 months ago

PolyPid to Participate in the 37th Annual ROTH Conference

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 10:44 AM EST - 11 months ago

PolyPid Ltd. (PYPD) Q4 2024 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Feb 12, 2025, 7:00 AM EST - 11 months ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 7:00 AM EST - 11 months ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Jan 29, 2025, 7:00 AM EST - 11 months ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

Dec 26, 2024, 10:31 AM EST - 1 year ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 23, 2024, 7:22 PM EST - 1 year ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 2:06 PM EST - 1 year ago

PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Nov 7, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 1:25 PM EDT - 1 year ago

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

Aug 1, 2024, 8:31 PM EDT - 1 year ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

Jul 31, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

Jun 10, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

Finnish_boy
Finnish_boy Dec. 26 at 2:54 PM
$PYPD
0 · Reply
ThermalTideT
ThermalTideT Dec. 26 at 2:44 PM
$PYPD Market structure is quietly punishing unfocused strategies. Operating rhythm should stabilize as learning cycles compress. Overextension would degrade optionality during downturns. Stronger outcomes appear only when priorities stay focused.
0 · Reply
tkcomputer
tkcomputer Dec. 23 at 5:57 PM
$PYPD Can't believe this was over a $200 stock a few years back! Understand there are probably stock splits in there somewhere but alot of people must have bought into their technology at some point!
2 · Reply
Finnish_boy
Finnish_boy Dec. 23 at 3:22 PM
$PYPD
0 · Reply
PaulWalter
PaulWalter Dec. 23 at 12:56 PM
$PYPD weird how mr market doesn’t recognise this. At all. .
2 · Reply
Finnish_boy
Finnish_boy Dec. 23 at 8:13 AM
$PYPD In a month US partnership deal, waiting is coming to end.. they are hiring loads of people on LinkedIn
0 · Reply
Finnish_boy
Finnish_boy Dec. 18 at 9:37 PM
$PYPD
0 · Reply
Finnish_boy
Finnish_boy Dec. 18 at 1:04 AM
$PYPD Tick tock, US partnership deal within a month! https://www.pharmanow.live/latest-news/polypid-brooke-story-chair
0 · Reply
Finnish_boy
Finnish_boy Dec. 16 at 7:30 PM
$PYPD $10 stock in 3 months !!
0 · Reply
PaulWalter
PaulWalter Dec. 16 at 4:41 PM
$PYPD So they’re just hiring someone to negotiate NOW????
2 · Reply
Finnish_boy
Finnish_boy Dec. 16 at 4:18 PM
$PYPD Warnings everywhere.. huge take-off in a month.. be ready guys !!!!
0 · Reply
Finnish_boy
Finnish_boy Dec. 16 at 4:15 PM
$PYPD Be patient. Price action can be flat this month. January huge take-off.. load up all you can !!!!!
1 · Reply
WallStWireAds
WallStWireAds Dec. 16 at 1:31 PM
$PYPD https://caplynx.io/1WpzZKz
0 · Reply
WallStWireAds
WallStWireAds Dec. 16 at 12:44 PM
$PYPD https://capnotes.beehiiv.com/p/when-a-world-renowned-surgeon-calls-it-a-paradigm-shift-it-may-be-time-for-investors-to-pay-attentio
0 · Reply
Doozio
Doozio Dec. 15 at 1:44 PM
$PYPD few weeks/few years who gives a fook. They have told YOU no FOLD now out of the tightness let’s bang bro. Everything happen It’s time…..🐒🍌🧠⏰♾️
0 · Reply
Finnish_boy
Finnish_boy Dec. 14 at 11:37 PM
$PYPD Listen especially this 29:20 -> part of the video. January will be huge! https://www.youtube.com/watch?v=uF8VxpyLJX0&t=1810s
0 · Reply
Finnish_boy
Finnish_boy Dec. 14 at 7:05 PM
$PYPD
0 · Reply
Finnish_boy
Finnish_boy Dec. 14 at 4:41 PM
$PYPD TOP34 surgerion in the world, top1 in own field: "I was very intrigued by this as being something really in my entire career that's new for SSI prevention. This is truly new. This is a paradigm shift for us. It represents a different direction. And that's what attracted me to it."
0 · Reply
Finnish_boy
Finnish_boy Dec. 13 at 2:27 AM
$PYPD
0 · Reply
Finnish_boy
Finnish_boy Dec. 12 at 11:45 PM
$PYPD My average about $3.9 (15k shares).. i will sell 5k shares at $10. Then i keep holding 10k shares on the road to $20. This amazing opportunity. Mgt and product are brilliant. Dont sleep. Load up before January!
0 · Reply
Finnish_boy
Finnish_boy Dec. 12 at 8:50 PM
$PYPD
0 · Reply
hegdaom
hegdaom Dec. 12 at 8:35 PM
$PYPD
0 · Reply